German drugmaker Boehringer Ingelheim is considering the sale of its U.S. generics unit Roxane Labs for as much as 2 billion euros ($2.36 billion), Bloomberg said, citing people with knowledge of the matter.

Boehringer Ingelheim officials were not immediately available for comment outside office hours.

The drugmaker is working with Morgan Stanley on the sale, two of the people told Bloomberg.

Boehringer may also be interested in pursuing asset swaps with competitors to bulk up its businesses such as prescription drugs, one of them said.